Aptevo Therapeutics (APVO) Profit After Tax (2015 - 2026)

Aptevo Therapeutics has reported Profit After Tax for 12 years, with the latest figure at -$6.7 million in Q1 2026.

• Quarterly Profit After Tax fell 4.51% year-over-year to -$6.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$26.3 million (down 10.77% YoY) and the FY2025 annual result came in at -$26.0 million, down 7.61% from the prior year.
• Profit After Tax eased to -$6.7 million in Q1 2026 per APVO's latest filing, from -$5.8 million in the prior quarter.
• Over five years, Profit After Tax peaked at $28.0 million in Q2 2022 and troughed at -$7.9 million in Q2 2023.
• A 5-year average of -$3.9 million and a median of -$6.3 million in 2024 frame the typical range for Profit After Tax.
• The sharpest annual moves came in 2022 and 2024: Profit After Tax soared 453.13% in 2022, then plunged 346.45% in 2024.
• Over 5 years, Profit After Tax stood at -$5.2 million in 2022, then slipped by 20.01% to -$6.2 million in 2023, then fell by 1.87% to -$6.3 million in 2024, then increased by 8.02% to -$5.8 million in 2025, then decreased by 15.35% to -$6.7 million in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered -$6.7 million, -$5.8 million, and -$7.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.